BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, while the distribution of BP-CML colony types was not affected by VEN or S63845 treatment, this was not the case for cells treated with A-1331852, indicating that BCL-xL inhibition restricts different hematopoietic lineages in vitro (Fig. 5C).